155 related articles for article (PubMed ID: 34528398)
21. Peripheral and periosteal chondrosarcoma: MRI-pathological correlation in 58 cases.
Tilden W; Andrei V; O'Donnell P; Saifuddin A
Skeletal Radiol; 2022 Jun; 51(6):1189-1199. PubMed ID: 34714386
[TBL] [Abstract][Full Text] [Related]
22. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype.
Cleven AH; Zwartkruis E; Hogendoorn PC; Kroon HM; Briaire-de Bruijn I; Bovée JV
Histopathology; 2015 Oct; 67(4):483-90. PubMed ID: 25648524
[TBL] [Abstract][Full Text] [Related]
23. Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.
Venneker S; Szuhai K; Hogendoorn PCW; Bovée JVMG
Virchows Arch; 2020 Jan; 476(1):135-146. PubMed ID: 31728625
[TBL] [Abstract][Full Text] [Related]
24. Somatic IDH1 mutation in a pituitary adenoma of a patient with Maffucci syndrome.
Hao S; Hong CS; Feng J; Yang C; Chittiboina P; Zhang J; Zhuang Z
J Neurosurg; 2016 Jun; 124(6):1562-7. PubMed ID: 26473790
[TBL] [Abstract][Full Text] [Related]
25. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
[TBL] [Abstract][Full Text] [Related]
26. GNAS mutation detection in circulating cell-free DNA is a specific predictor for intraductal papillary mucinous neoplasms of the pancreas, especially for intestinal subtype.
Hata T; Mizuma M; Motoi F; Omori Y; Ishida M; Nakagawa K; Hayashi H; Morikawa T; Kamei T; Furukawa T; Unno M
Sci Rep; 2020 Oct; 10(1):17761. PubMed ID: 33082481
[TBL] [Abstract][Full Text] [Related]
27. GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms.
Gaujoux S; Parvanescu A; Cesaretti M; Silve C; Bieche I; Rebours V; Lévy P; Sauvanet A; Cros J
Ann Surg Oncol; 2019 Aug; 26(8):2640-2650. PubMed ID: 31025231
[TBL] [Abstract][Full Text] [Related]
28. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
[TBL] [Abstract][Full Text] [Related]
29. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
30. Identification of novel GNAS mutations in intramuscular myxoma using next-generation sequencing with single-molecule tagged molecular inversion probes.
Bekers EM; Eijkelenboom A; Rombout P; van Zwam P; Mol S; Ruijter E; Scheijen B; Flucke U
Diagn Pathol; 2019 Feb; 14(1):15. PubMed ID: 30736805
[TBL] [Abstract][Full Text] [Related]
31. Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma.
Warmke LM; Cheng L; Sperling RM; Sen JD; Ulbright TM
Mod Pathol; 2022 Nov; 35(11):1636-1643. PubMed ID: 35660795
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Turner NC; Kingston B; Kilburn LS; Kernaghan S; Wardley AM; Macpherson IR; Baird RD; Roylance R; Stephens P; Oikonomidou O; Braybrooke JP; Tuthill M; Abraham J; Winter MC; Bye H; Hubank M; Gevensleben H; Cutts R; Snowdon C; Rea D; Cameron D; Shaaban A; Randle K; Martin S; Wilkinson K; Moretti L; Bliss JM; Ring A
Lancet Oncol; 2020 Oct; 21(10):1296-1308. PubMed ID: 32919527
[TBL] [Abstract][Full Text] [Related]
33. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
Pietrantonio F; Berenato R; Maggi C; Caporale M; Milione M; Perrone F; Tamborini E; Baratti D; Kusamura S; Mariani L; Niger M; Mennitto A; Gloghini A; Bossi I; Settanni G; Busico A; Bagnoli PF; Di Bartolomeo M; Deraco M; de Braud F
J Transl Med; 2016 May; 14(1):125. PubMed ID: 27154293
[TBL] [Abstract][Full Text] [Related]
34. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
[TBL] [Abstract][Full Text] [Related]
35. Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC.
Mu N; Jylhä C; Axelsson T; Sydén F; Brehmer M; Tham E
World J Urol; 2023 Dec; 41(12):3421-3427. PubMed ID: 37721600
[TBL] [Abstract][Full Text] [Related]
36. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
[TBL] [Abstract][Full Text] [Related]
37. GNAS Mutations: Drivers or Co-Pilots? Yet, Promising Diagnostic Biomarkers.
Innamorati G; Valenti MT; Giacomello L; Dalle Carbonare L; Bassi C
Trends Cancer; 2016 Jun; 2(6):282-285. PubMed ID: 28741526
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of IDH mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma.
Huang X; Duijf PHG; Sriram S; Perera G; Vasani S; Kenny L; Leo P; Punyadeera C
J Biomed Sci; 2023 Aug; 30(1):65. PubMed ID: 37559138
[TBL] [Abstract][Full Text] [Related]
40. GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.
Ritterhouse LL; Vivero M; Mino-Kenudson M; Sholl LM; Iafrate AJ; Nardi V; Dong F
Mod Pathol; 2017 Dec; 30(12):1720-1727. PubMed ID: 28776576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
